CGEN

Compugen Ltd

2.09

USD

-0.05

-2.34%

Nov 10, 15:59 UTC -5

Closed

After-Market

2.12

+0.03

+1.34%

Compugen Ltd (CGEN) Earnings

CGEN Earnings Reports

Positive Surprise Ratio

CGEN beat 31 of 43 last estimates.

72%

Next Report

Date of Next Report

Mar 01, 2027

Estimate for Q4 26 (Revenue/ EPS)

$6.83M

-$0.04

Implied change from Q3 26 (Revenue/ EPS)

+78.90%

-33.33%

Implied change from Q4 25 (Revenue/ EPS)

-89.85%

-106.67%

Compugen Ltd earnings per share and revenue

On Nov 09, 2026, CGEN reported earnings of -0.06 USD per share (EPS) for Q3 26, beating the estimate of -0.08 USD, resulting in a 26.47% surprise. Revenue reached 3.82 million, compared to an expected 1.73 million, with a 120.30% difference. The market reacted with a +9.18% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.04 USD, with revenue projected to reach 6.83 million USD, implying an decrease of -33.33% EPS, and increase of 78.90% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Compugen Ltd's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Compugen Ltd reported EPS of -$0.06, beating estimates by 26.47%, and revenue of $3.82M, 120.3% above expectations.

How did the market react to Compugen Ltd's Q3 2026 earnings?

The stock price moved up 9.18%, changed from $1.96 before the earnings release to $2.14 the day after.

When is Compugen Ltd expected to report next?

The next earning report is scheduled for Mar 01, 2027.

What are the forecasts for Compugen Ltd's next earnings report?

Based on -- analysts, Compugen Ltd is expected to report EPS of -$0.04 and revenue of $6.83M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.